期刊论文详细信息
Cancer Communications
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR : what’s new and what’s enough
Fei Zhou1  Cai-Cun Zhou1 
[1] Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, P. R. China
关键词: Epidermal growth factor receptor (EGRF);    EGFR mutation;    Anaplastic lymphoma kinase (ALK);    ALK rearrangement;    Molecular targeted therapy;    Non-small cell lung cancer;   
DOI  :  10.1186/s40880-015-0036-4
学科分类:肿瘤学
来源: Springer
PDF
【 摘 要 】

Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC, this malignancy has been recently divided into several distinct subtypes according to the specific molecular alterations. This new paradigm has substantially highlighted the treatment of advanced NSCLC, shifting it from standard chemotherapy according to specific histologic subtypes to targeted therapy according to specific oncogenic drivers. The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring activating EGFR mutations has been a representative model of precise medicine in the treatment of NSCLC. As the role of EGFR-TKIs in routine management of patients with advanced NSCLC has been well established, this review provides an overview of alternative targeted therapy in the treatment of NSCLC, including EGFR-TKIs for patients with wild-type EGFR NSCLC, as well as other targeted agents either clinical available or in early- to late-stage development.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO201901227767618ZK.pdf 839KB PDF download
  文献评价指标  
  下载次数:4次 浏览次数:2次